Effect of Natalizumab on Circulating CD4+ T-Cells in Multiple Sclerosis

@inproceedings{Brnsen2012EffectON,
  title={Effect of Natalizumab on Circulating CD4+ T-Cells in Multiple Sclerosis},
  author={Lars B{\"o}rnsen and Jeppe Romme Christensen and Rikke Lenhard Ratzer and Annette Bang Oturai and Per Soelberg S\orensen and Helle Bach S\ondergaard and Finn Thorup Sellebjerg},
  booktitle={PloS one},
  year={2012}
}
In multiple sclerosis (MS), treatment with the monoclonal antibody natalizumab effectively reduces the formation of acute lesions in the central nervous system (CNS). Natalizumab binds the integrin very late antigen (VLA)-4, expressed on the surface of immune cells, and inhibits VLA-4 dependent transmigration of circulating immune-cells across the vascular endothelium into the CNS. Recent studies suggested that natalizumab treated MS patients have an increased T-cell pool in the blood… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarate

Neurology(R) neuroimmunology & neuroinflammation • 2017
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Similar Papers

Loading similar papers…